{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Myasthenia+Gravis",
    "query": {
      "condition": "Ocular Myasthenia Gravis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Myasthenia+Gravis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T02:40:06.686Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06558279",
      "title": "A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis, Ocular"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PH20 SC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2024-09-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06558279"
    },
    {
      "nct_id": "NCT06312644",
      "title": "Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ultomiris-exposed Pregnant/ Postpartum",
        "Pregnancy",
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "Atypical Hemolytic Uremic Syndrome (aHUS)",
        "Generalized Myasthenia Gravis (gMG)",
        "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Ultomiris",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 75,
      "start_date": "2024-12-16",
      "completion_date": "2034-07-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312644"
    },
    {
      "nct_id": "NCT07463521",
      "title": "A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Rozanolixizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2026-05-27",
      "completion_date": "2029-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 2,
      "location_summary": "Amherst, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07463521"
    },
    {
      "nct_id": "NCT02189720",
      "title": "Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Congenital Myasthenic Syndrome",
        "Lambert-Eaton Myasthenic Syndrome",
        "Nystagmus, Acquired"
      ],
      "interventions": [
        {
          "name": "Amifampridine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189720"
    },
    {
      "nct_id": "NCT02761707",
      "title": "Biomarkers in Neural Disorders",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease",
        "Alzheimer's Disease",
        "Progressive Supranuclear Palsy",
        "Essential Tremor",
        "Multiple System Atrophy",
        "Drug Induced Parkinson's Disease",
        "Diffuse Lewy Body Disease",
        "Myasthenia Gravis",
        "Spinal Cord Injuries"
      ],
      "interventions": [
        {
          "name": "Electrical Brainstem Responses",
          "type": "OTHER"
        },
        {
          "name": "Olfactory Tests",
          "type": "OTHER"
        },
        {
          "name": "Visual Deprivation",
          "type": "OTHER"
        },
        {
          "name": "Peripheral Nerve Stimulation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 54,
      "start_date": "2016-06",
      "completion_date": "2019-07-16",
      "has_results": false,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02761707"
    },
    {
      "nct_id": "NCT03818204",
      "title": "Clinical Trial to Improve the Magnetic Levator Prosthesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blepharoptosis",
        "Ptosis, Eyelid",
        "Myasthenia Gravis",
        "Stroke",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Magnetic Levator Prosthesis (MLP)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2019-02-07",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818204"
    },
    {
      "nct_id": "NCT03941184",
      "title": "Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SCAD",
        "Addison Disease",
        "Ankylosing Spondylitis",
        "Antiphospholipid Antibody Syndrome",
        "Celiac Disease",
        "Crohn Disease",
        "Dermatomyositis",
        "Polymyositis",
        "Guillain-Barre Syndrome",
        "Hepatitis, Autoimmune",
        "Graves Disease",
        "Hashimoto Thyroiditis",
        "Multiple Sclerosis",
        "Myasthenia Gravis",
        "Pernicious Anemia",
        "Polymyalgia Rheumatica",
        "Primary Biliary Cirrhosis",
        "Psoriasis",
        "Rheumatoid Arthritis",
        "Systemic Sclerosis",
        "Sjögren Syndrome",
        "Systemic Lupus Erythematosus",
        "Takayasu Arteritis",
        "Type 1 Diabetes Mellitus",
        "Ulcerative Colitis",
        "Uveitis",
        "Vasculitis",
        "Vitiligo",
        "Raynaud"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 114,
      "start_date": "1995-01-01",
      "completion_date": "2020-11-10",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03941184"
    },
    {
      "nct_id": "NCT07250750",
      "title": "A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "IM-101 Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo Part A",
          "type": "DRUG"
        },
        {
          "name": "IM-101 Part B",
          "type": "DRUG"
        },
        {
          "name": "Placebo Part B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunAbs Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 96,
      "start_date": "2026-02-05",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 8,
      "location_summary": "Altamonte Springs, Florida • Boca Raton, Florida • Naples, Florida + 4 more",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07250750"
    },
    {
      "nct_id": "NCT00716066",
      "title": "Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Disease",
        "Neurologic Autoimmune Disease",
        "Autologous Transplant Autoimmune",
        "Multiple Sclerosis Transplant",
        "MS Stem Cell Transplant",
        "Multiple Sclerosis Stem Cell Transplant",
        "Stiff Person Syndrome",
        "HCT for Neurologic Autoimmune Disorders",
        "CIDP Transplant",
        "Myasthenia Gravis Transplant",
        "Autoimmune Nervous System Disorder",
        "Central Nervous System Vasculitis",
        "Cerebellar Degeneration",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Lambert Eaton Myasthenic Syndrome",
        "Myasthenia Gravis",
        "Neuromyelitis Optica",
        "Opsoclonus Myoclonus Syndrome",
        "Rasmussen Subacute Encephalitis"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Syngeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "71 Years",
        "sex": "ALL",
        "summary": "Up to 71 Years"
      },
      "enrollment_count": 53,
      "start_date": "2008-06",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716066"
    },
    {
      "nct_id": "NCT06680037",
      "title": "A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Mediated Autoimmune Disorders"
      ],
      "interventions": [
        {
          "name": "Azercabtagene zapreleucel (azer-cel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-05-06",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-22T02:40:06.686Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06680037"
    }
  ]
}